Immune to Cancer: The CRI Blog
-
First Monoclonal Antibody for Multiple Myeloma Receives FDA Approval
Daratumumab (Darzalex®) is the first approved immunotherapy that targets CD38—a protein found in most multiple myeloma cells.
-
CRI Feels the LOVE and Wins $250,000!
Thanks to our donors, we won second place in the Revlon LOVE IS ON Million Dollar Challenge.
-
Second Annual Immuno-Oncology 360° Conference
CRI Scientific Advisory Council member to co-chair two-day conference devoted to cancer immunotherapy.
-
Making It Count: Team CRI Adds On Miles for Cancer Research
Meet a few of the Team CRI members who ran in the 2015 TCS New York City…
-
FDA Approves Immunotherapy to Help Prevent Relapse of Melanoma
The immunotherapy drug ipilimumab (Yervoy®) can now be used to help prevent relapse after surgery.
-
FDA Approves First in a New Class of Immunotherapies
Amgen’s oncolytic virus immunotherapy, T-VEC, gets the green light from the FDA.
-
What Is an Oncogene? Immunologists Rethink a Fundamental Cancer Concept
Immunology is reshaping how oncologists think about cancer, and even basic principles—like oncogenes—are getting a significant makeover.
-
FDA Approves Expanded Use of Nivolumab for Lung Cancer
Nivolumab, a PD-1 immunotherapy, is now approved as second-line therapy for the most common type of lung…
-
FDA Approves PD-1 Immunotherapy for Most Common Type of Lung Cancer
Patients with non-small cell lung cancer may now receive a PD-1 immunotherapy as second-line treatment after chemotherapy.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.